Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATNMNASDAQ:EGRXNASDAQ:ELYMNASDAQ:FLKS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.50+2.7%$1.52$1.03▼$8.64$46.79M-0.27505,431 shs255,065 shsEGRXEagle Pharmaceuticals$2.88+22.3%$1.99$1.50▼$2.88$37.34M0.839,550 shs742 shsELYMEliem Therapeutics$1.23+2.5%$1.26$2.35▼$11.55$36.60M-0.39486,688 shs283,275 shsFLKSFlex Pharma$1.08+2.9%$6.86$0.26▼$1.49$19.52M1.652.03 million shs2.02 million shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals+2.74%+0.67%-12.28%-3.23%-81.60%EGRXEagle Pharmaceuticals+22.34%+19.79%+74.24%+92.95%-27.22%ELYMEliem Therapeutics0.00%-3.91%-0.81%-5.38%-83.27%FLKSFlex Pharma0.00%+52.76%+37.54%+13.31%-63.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNMActinium Pharmaceuticals1.1818 of 5 stars3.42.00.00.00.00.00.6EGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AELYMEliem TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AFLKSFlex PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNMActinium Pharmaceuticals 2.75Moderate Buy$4.00166.67% UpsideEGRXEagle Pharmaceuticals 0.00N/AN/AN/AELYMEliem Therapeutics 0.00N/AN/AN/AFLKSFlex Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest FLKS, ATNM, ELYM, and EGRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/28/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/1/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/25/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNMActinium Pharmaceuticals$81K577.70N/AN/A$1.31 per share1.15EGRXEagle Pharmaceuticals$257.55M0.14$7.19 per share0.40N/A∞ELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/AFLKSFlex Pharma$840K23.23N/AN/A$0.51 per share2.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNMActinium Pharmaceuticals-$48.82M-$1.39N/AN/AN/AN/A-100.85%-47.89%N/AEGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/AELYMEliem Therapeutics-$35.12M-$0.53N/A∞N/AN/A-47.03%-45.97%N/AFLKSFlex Pharma-$21.92MN/A0.00∞N/A-1,208.42%-98.04%-83.37%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNMActinium PharmaceuticalsN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AELYMEliem TherapeuticsN/AN/AN/AN/AN/AFLKSFlex PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNMActinium PharmaceuticalsN/A10.2510.25EGRXEagle PharmaceuticalsN/AN/AN/AELYMEliem TherapeuticsN/A60.4160.41FLKSFlex PharmaN/A6.866.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNMActinium Pharmaceuticals27.50%EGRXEagle Pharmaceuticals85.36%ELYMEliem Therapeutics69.76%FLKSFlex Pharma14.42%Insider OwnershipCompanyInsider OwnershipATNMActinium Pharmaceuticals6.00%EGRXEagle Pharmaceuticals28.90%ELYMEliem Therapeutics4.70%FLKSFlex Pharma7.62%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataELYMEliem Therapeutics929.75 million28.35 millionNot OptionableFLKSFlex Pharma418.07 millionN/ANot OptionableFLKS, ATNM, ELYM, and EGRX HeadlinesRecent News About These CompaniesFLEX LNG: A Bond-Like 11.9% Yield To Lock Before Rate CutsSeptember 9, 2024 | seekingalpha.comFitbit Flex 2 reviewAugust 16, 2024 | stuff.tvFLEX LNG Ltd. (FLNG) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | seekingalpha.comConstruction Partners, Inc. (ROAD) Q3 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comWayfair Inc. (W) Q2 2024 Earnings Call TranscriptAugust 3, 2024 | seekingalpha.comQ2 2024 AGCO Corp Earnings CallJuly 31, 2024 | finance.yahoo.comRotary Releases New Remote-Controlled Flex MAX Linker for Safely Connecting Mobile Column LiftsJuly 25, 2024 | stnonline.comCommentary: By rejecting 340B expansion, Youngkin put patients before profitsJuly 24, 2024 | richmond.comFlex Ltd. (FLEX) Q1 2025 Earnings Call TranscriptJuly 24, 2024 | seekingalpha.comFlex lanes are coming to Central Florida toll roads. Here’s what they doMay 28, 2024 | clickorlando.comFlex Ltd.: Undervalued With Solid FundamentalsApril 4, 2024 | seekingalpha.comflex couplerDecember 20, 2023 | hackaday.comUsed Ford Flex for sale under $10,000 near meNovember 30, 2023 | cars.comFLEX LNG Ltd. 2023 Q3 - Results - Earnings Call PresentationNovember 17, 2023 | seekingalpha.comUnforgettable Patients: A guy came to the ER for a scratch on his neck and "feeling drowsy." As we start the routine workups, he suddenly drops dead. Days later, his autopsy ...October 30, 2023 | msn.comGrand Forks Movie TheatresOctober 26, 2023 | tribute.caANGLE release Portrait Flex CTC assaySeptember 4, 2023 | msn.comWhy flex work is as important as pay for someSeptember 1, 2023 | msn.comNovartis flexes PhIII win for oral BTK inhibitor in chronic spontaneous urticariaAugust 9, 2023 | endpts.comSpring cleanup week in Greater Grand Forks postponed to late May due to spring snowfallJune 30, 2023 | grandforksherald.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFLKS, ATNM, ELYM, and EGRX Company DescriptionsActinium Pharmaceuticals NYSE:ATNM$1.50 +0.04 (+2.74%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.50 0.00 (0.00%) As of 06/20/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.Eagle Pharmaceuticals NASDAQ:EGRX$2.88 +0.53 (+22.34%) As of 06/20/2025 03:42 PM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Eliem Therapeutics NASDAQ:ELYM$1.23 +0.03 (+2.50%) As of 06/18/2025Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Flex Pharma NASDAQ:FLKSFlex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise-associated muscle cramps in the United States. It operates in two segments, Consumer Operations and Drug Development. The company's lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which completed an exploratory Phase II clinical trial in Australia for the treatment of patients with multiple sclerosis. It also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. The company markets and sells its HOTSHOT products online through its direct-to-consumer Website and through third-party Websites, including a retailer that offers international shipping. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
